Recent preeclampsia studies have investigated predictors such as placenta location and PAPP-A, in addition to comparing the P/C ratio with 24-hour proteinuria.
Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; "Renalys Pharma") announced today that it has completed patient enrollment for its registrational Phase III clinical trial of sparsentan for the ...
Researchers identified a key protein as a potential therapeutic target for stopping the body's immune system from mistakenly attacking itself, offering new hope for treating autoimmune diseases and ...